Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookie, but we will activate these services only with your consent. If you press the button “Accept”, you consent to the use of these analytics scripts.

You can withdraw your consent at any time. To do so, please modify your configurations on this website by following this link to our privacy statement with the configuration options:
Go to settings

Accept

;

What we have to offer – and what we seek

We are known for our expertise in pain. Strong partnerships are fundamental to our success and our track record in this area is exceptional. Many of our partners have been working with us for several years – and are keen to extend our business relationship into the future.

We put this success down to good communication, excellent compliance standards, strong business development and access to attractive markets, as well as our integrated strategic Alliance Management. Our partners value Grünenthal’s state-of-the-art production facilities and high-quality products. We strengthen and develop our core markets in Europe and Latin America through acquisitions, asset deals, in-licensing, commercialisation and distribution deals.

Europe

In this region, we focus on well established brands that closely fit our existing commercial footprint – independent of specific therapeutic areas or indications. In addition, as a global leader in pain R&D, pain is our core business. We are interested in partnerships for late-stage (phII-III) pain development projects.

This includes:

  • Peripheral neuropathic pain
  • Chronic post-surgical pain
  • Chronic low back pain
  • Osteoarthritis
  • Migraine

North America

We are building a preeminent pain management company to address the US market. We are open to working with parties to help build our ecosystem of healthcare to provide patients with comprehensive pain management, based on three pillars: product, platform and pipeline.

Latin America

In this region, we operate one of the leading platforms – and it covers all key markets. We focus on products in late-stage clinical development that are ready to be filed or marketed, as well as to take over the local representation of existing companies and their portfolio within our therapeutic key areas or fit to our sales footprint.

This includes treatments for:

  • Pain
  • CNS
  • Women’s health
  • and adjacent therapies outside of these therapeutic areas, that are prescribed by the same target audience.

Out-Licensing

We are actively seeking new opportunities to collaborate, from co-development and co-marketing through to co-promotion and licensing. Grünenthal is particularly interested in out-licensing in countries and regions where we haven’t yet established a presence through subsidiaries, such as Canada, the Middle East, and Asia – especially Japan, China and Africa.

Research and Development

As a global leader in pain, our mission is to find breakthrough solutions for our patients. In order to achieve this we are combining our deep understanding of pain and proven experience in developing innovative pain treatments with novel, innovative and impactful ideas of our partners.  We are seeking R&D collaborations that focus on pain indications and, independent of their stage of development and modality, have the potential to make a real difference to patients.

Get in touch

We’re keen to hear new ideas and discover assets that are relevant to our business. If you’re interested in partnering with us, get in touch.
... Contact us